Drug Trial Radar · NCT00063804
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Not stated
Primary completion
Not stated
Study completion Oct 2006
Sponsor
- Sponsor type
- NIH
- Collaborators
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- First posted
- Jul 8, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who have developed resistance to or are unable to take other anti-HIV drugs. This study will evaluate the safety of different doses of AMD070 along with AMD070 boosted with ritonavir (RTV) in HIV uninfected men.
Conditions
- HIV Infections
Interventions
RitonavirDrug
AMD070Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- AMD070 pharmacokinetic (PK) parameters under three conditions, and the within-volunteer differences between them
- Steady-state RTV PK parameters
- Grade 3 and 4 adverse effects, as defined by the protocol
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Adult AIDS CRS
Baltimore, Maryland
University of Washington AIDS CRS
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.